Table 1:

Patient characteristics and outcomes

Patient characteristics	N, %	Death	Death/Intubation/High Flow nasal cannula
Gender Female Male	28, 43% 37, 57%	3, 11% 8, 22%	7, 25% 12, 32%
Age median, range > 60 years old < 60 years old	65, 20–83 36, 55% 29, 45%	9, 25% 2, 7%	15, 42% 4, 14%
Disease AML ALL CML CLL MDS MPN	17, 26% 6, 9% 7, 11% 25, 38% 3, 5% 7, 11%	6, 35% 1, 17% 0, 0% 2, 8% 0, 0% 2, 29%	8, 47% 1, 17% 1, 14% 6, 24% 1, 33% 2, 29%
Treatment prior to COVID-19 treatment < 3 months ago treatment > 3 months ago/never treated prior allogeneic stem cell transplant	34, 52% 31, 48% 16, 25%	9, 26% 2, 6% 4, 25%	11,32% 8, 26% 7, 44%
Neutropenia: ANC < 1000/uL Lymphocytopenia: ALC < 500/uL	14, 22% 21, 38%	7, 50% 5, 24%	8, 57% 10, 21%
COVID-19 directed therapy No treatment required Hydroxychloroquine Convalescent plasma Tocilizumab Remdesivir Azithromycin Dexamethasone	34, 52% 21, 32% 12, 19% 5, 8% 3, 5% 16, 25% 5, 8%	2, 5% 7, 33% 2, 17% 3, 60% 1, 33% 4, 25% 2, 40%	3, 9% 13, 62% 5, 41% 4, 80% 2, 67% 8, 50% 3, 60%
Administration of G-CSF	8, 12%	2, 25%	3, 38%